Chemoprevention of prostate cancer

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 111-123

  Vemana, Goutham ^a   Hamilton, Robert J ^b   Andriole, Gerald L ^a   Freedland, Stephen J ^c,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 alpha reductase inhibitors; Dutasteride; Finasteride; Primary prevention; Prostate neoplasm

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CAFFEINE; DUTASTERIDE; ESTROGEN RECEPTOR; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; SELENIUM; TOREMIFENE;

AGGRESSION; ALCOHOL CONSUMPTION; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; META ANALYSIS (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PREVENTION STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SABAL; SMOKING; SYSTEMATIC REVIEW (TOPIC);

5-ALPHA REDUCTASE INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZASTEROIDS; CAROTENOIDS; DIETARY SUPPLEMENTS; FINASTERIDE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MALE; PLANT EXTRACTS; PRIMARY PREVENTION; PROSTATIC NEOPLASMS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SELENIUM; VITAMIN E;

EID: 84901494493     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-121211-091759     Document Type: Article

References (82)

1. Masko EM, Allott EH, Freedland SJ. 2013. The relationship between nutrition and prostate cancer: Is more always better? Eur. Urol. 63:810-20
2. Kruk J, Czerniak U. 2013. Physical activity and its relation to cancer risk: updating the evidence. Asian Pac. J. Cancer Prev. 14:3993-4003
3. Liu Y, Hu F, Li D, et al. 2011. Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Eur. Urol. 60:1029-44
4. Rebillard A, Lefeuvre-Orfila L, Gueritat J, Cillard J. 2013. Prostate cancer and physical activity: adaptive response to oxidative stress. Free Radic. Biol. Med. 60:115-24
5. Jones LW, Antonelli J, Masko EM, et al. 2012. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J. Appl. Physiol. 1985 113:263-72
6. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. 2011. Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-up Study. J. Clin. Oncol. 29:726-32
7. Freedland SJ, Mavropoulos J, Wang A, et al. 2008. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 68:11-19
8. Roddam AW, Allen NE, Appleby P, et al. 2008. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann. Intern. Med. 149:461-71
9. Drake I, Sonestedt E, Gullberg B, et al. 2012. Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmo Diet and Cancer cohort. Am. J. Clin. Nutr. 96:1409-18
10. Egeberg R, Olsen A, Christensen J, et al. 2011. Intake of whole-grain products and risk of prostate cancer among men in the Danish Diet, Cancer and Health cohort study. Cancer Causes Control 22:1133-39
11. Nimptsch K, Kenfield S, Jensen MK, et al. 2011. Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer. Cancer Causes Control 22:51-61
12. Kobayashi N, Barnard RJ, Said J, et al. 2008. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res. 68:3066-73 (Pubitemid 351556309)
13. Wallstrom P, Bjartell A, Gullberg B, et al. 2007. A prospective study on dietary fat and incidence of prostate cancer (Malmo, Sweden). Cancer Causes Control 18:1107-21 (Pubitemid 47498160)
14. Williams CD, Whitley BM, Hoyo C, et al. 2011. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr. Res. 31:1-8
15. Aronson WJ, Kobayashi N, Barnard RJ, et al. 2011. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev. Res. (Phila) 4:2062-71
16. Brasky TM, Darke AK, Song X, et al. 2013. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J. Natl. Cancer Inst. 105:1132-41
17. Richman EL, Kenfield SA, Chavarro JE, et al. 2013. Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality. JAMA Intern. Med. 173:1318-26
18. Liu B, Mao Q, Cao M, Xie L. 2012. Cruciferous vegetables intake and risk of prostate cancer: a metaanalysis. Int. J. Urol. 19:134-41
19. Yan L, Spitznagel EL. 2009. Soy consumption and prostate cancer risk inmen: a revisit of a meta-analysis. Am. J. Clin. Nutr. 89:1155-63
20. Bosland MC, Kato I, Zeleniuch-Jacquotte A, et al. 2013. Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA 310:170-78
21. HuncharekM, Muscat J, Kupelnick B. 2008. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26, 769 cases from 45 observational studies. Nutr. Cancer 60:421-41 (Pubitemid 351918540)
22. Discacciati A, Orsini N, Wolk A. 2012. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann. Oncol. 23:1665-71
23. Allott EH, Masko EM, Freedland SJ. 2013. Obesity and prostate cancer: weighing the evidence. Eur. Urol. 63:800-9
24. Huncharek M, Haddock KS, Reid R, Kupelnick B. 2010. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am. J. Public Health 100:693-701
25. Rota M, Scotti L, Turati F, et al. 2012. Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-risk relation. Eur. J. Cancer Prev. 21:350-59
26. Park C-H, Myung S-K, Kim T-Y, et al. 2010. Coffee consumption and risk of prostate cancer: a metaanalysis of epidemiological studies. BJU Int. 106:762-69
27. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. 1974. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186:1213-15
28. Thigpen AE, Davis DL, Gautier T, et al. 1992. Brief report: themolecular basis of steroid 5 alpha-reductase deficiency in a large Dominican kindred. N. Engl. J. Med. 327:1216-19
29. Andriole GL, Guess HA, Epstein JI, et al. 1998. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 52:195-201; discussion 202
30. McConnell JD, Roehrborn CG, Bautista OM, et al. 2003. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349:2387-98 (Pubitemid 37542987)
31. Andriole GL, Roehrborn C, Schulman C, et al. 2004. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64:537-41; discussion 542-43
32. Roehrborn CG, Siami P, Barkin J, et al. 2010. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 57:123-31
33. McConnell JD, Bruskewitz R, Walsh P, et al. 1998. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl. J. Med. 338:557-63
34. Thompson IM, Goodman PJ, Tangen CM, et al. 2003. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349:215-24 (Pubitemid 36859473)
35. Cohen YC, Liu KS, Heyden NL, et al. 2007. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 99:1366-74 (Pubitemid 351767189)
36. Lucia MS, Epstein JI, Goodman PJ, et al. 2007. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 99:1375-83 (Pubitemid 351767184)
37. Clark RV, Hermann DJ, Cunningham GR, et al. 2004. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J. Clin. Endocrinol. Metab. 89:2179-84 (Pubitemid 38619850)
38. Andriole G, Bostwick D, Brawley O, et al. 2004. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J. Urol. 172:1314-17 (Pubitemid 39249705)
39. Theoret MR, Ning YM, Zhang JJ, et al. 2011. The risks and benefits of 5 alpha-reductase inhibitors for prostate-cancer prevention. N. Engl. J. Med. 365:97-99
40. Thompson IM, Goodman PJ, Tangen CM, et al. 2013. Long term survival of participants in the Prostate Cancer Prevention Trial. N. Engl. J. Med. 369:603-10
41. Robinson D, Garmo H, Bill-Axelson A, et al. 2013. Use of 5 alpha-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ 346:1-10
42. Andriole GL, Bostwick DG, Brawley OW, et al. 2010. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362:1192-202
43. Sfanos KS, De Marzo AM. 2012. Prostate cancer and inflammation: the evidence. Histopathology 60:199- 215
44. Gupta S, Srivastava M, Ahmad N, et al. 2000. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42:73-78 (Pubitemid 30004877)
45. Narayanan BA, NarayananNK, Pittman B, Reddy BS. 2004. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. 10:7727-37 (Pubitemid 39557538)
46. Mahmud SM, Franco EL, Aprikian AG. 2010. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int. J. Cancer 127:1680-91
47. van Adelsberg J, Gann P, Ko AT, et al. 2007. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr. Med. Res. Opin. 23:2063-70 (Pubitemid 350246594)
48. Wang C, TaoW, Wang Y, et al. 2010. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur. Urol. 58:418-26
49. Zhuang L, Kim J, Adam RM, et al. 2005. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. 115:959-68 (Pubitemid 40489400)
50. Hamilton RJ, Goldberg KC, PlatzEA, Freedland SJ. 2008. The influence of statinmedications on prostatespecific antigen levels. J. Natl. Cancer Inst. 100:1511-18
51. Chang SL, Harshman LC, Presti JC. 2010. Impact of common medications on serum total prostatespecific antigen levels: analysis of the National Health and Nutrition Examination Survey. J. Clin. Oncol. 28:3951-57
52. Freedland SJ, Hamilton RJ, Gerber L, et al. 2013. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Diseases 16:254-59
53. Bansal D, Undela K, D'Cruz S, Schifano F. 2012. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE 7:e46691
54. Park HS, Schoenfeld JD, Mailhot RB, et al. 2013. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann. Oncol. 24:1427-34
55. Hamilton RJ, Freedland SJ. 2008. Rationale for statins in the chemoprevention of prostate cancer. Curr. Urol. Rep. 9:189-96 (Pubitemid 351769002)
56. Li YC, Park MJ, Ye S-K, et al. 2006. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 168:1107-18
57. Li L, Ren CH, Tahir SA, et al. 2003. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Cell Biol. 23:9389-404 (Pubitemid 37499824)
58. Hall SA, Page ST, Travison TG, et al. 2007. Do statins affect androgen levels in men? Results from the Boston Area Community Health Survey. Cancer Epidemiol. Biomark. Prev. 16:1587-94 (Pubitemid 47294823)
59. Mostaghel EA, Solomon KR, Pelton K, et al. 2012. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE 7:e30062
60. Ghosh PM, Ghosh-Choudhury N, Moyer ML, et al. 1999. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18:4120-30 (Pubitemid 29363919)
61. Lee J, Lee I, Park C, Kang WK. 2006. Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem. Biophys. Res. Commun. 339:748-54 (Pubitemid 41772877)
62. Banez LL, Klink JC, Jayachandran J, et al. 2010. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol. Biomark. Prev. 19:722-28
63. Ehara H, Koji T, Deguchi T, et al. 1995. Expression of estrogen receptor in diseased human prostate assessed by non-radioactive in situ hybridization and immunohistochemistry. Prostate 27:304-13
64. Prins GS, Huang L, Birch L, Pu Y. 2006. The role of estrogens in normal and abnormal development of the prostate gland. Ann. NY Acad. Sci. 1089:1-13 (Pubitemid 47092064)
65. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. 2002. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 62:1370-76 (Pubitemid 34407794)
66. Price D, Stein B, Sieber P, et al. 2006. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J. Urol. 176:965-70; discussion 970-71
67. Taneja SS, Morton R, Barnette G, et al. 2013. Prostate cancer diagnosis among men with isolated highgrade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J. Clin. Oncol. 31:523-29
68. Eisenberg DM, Davis RB, Ettner SL, et al. 1998. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280:1569-75 (Pubitemid 28520643)
69. Bailey RL, Gahche JJ, Lentino CV, et al. 2011. Dietary supplement use in the United States, 2003-2006. J. Nutr. 141:261-66
70. Preuss HG, Marcusen C, Regan J, et al. 2001. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int. Urol. Nephrol. 33:217-25 (Pubitemid 34575369)
71. Zachara BA, Szewczyk-Golec K, Wolski Z, et al. 2005. Selenium level in benign and cancerous prostate. Biol. Trace Elem. Res. 103:199-206 (Pubitemid 40628895)
72. Lippman SM, Klein EA, Goodman PJ, et al. 2009. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39-51
73. Locke J, Hersey K, Margel D, et al. 2013. Prevalence and predictors of selenium and vitamin E supplementation in a urology population. J. Altern. Complement. Med. 19:128-33
74. Rao AV, Agarwal S. 2000. Role of antioxidant lycopene in cancer and heart disease. J. Am. Coll. Nutr. 19:563-69
75. Obermuller-Jevic UC, Olano-Martin E, Corbacho AM, et al. 2003. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J. Nutr. 133:3356-60 (Pubitemid 37409459)
76. Kristal AR, Arnold KB, Schenk JM, et al. 2008. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am. J. Epidemiol. 167:925-34 (Pubitemid 351521732)
77. Ilic D, Misso M. 2012. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas 72:269-76
78. Marks LS, Hess DL, Dorey FJ, et al. 2001. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 57:999-1005 (Pubitemid 32405333)
79. Bonnar-Pizzorno RM, Littman AJ, Kestin M, White E. 2006. Saw palmetto supplement use and prostate cancer risk. Nutr. Cancer 55:21-27 (Pubitemid 44477041)
80. Bent S, Kane C, Shinohara K, et al. 2006. Saw palmetto for benign prostatic hyperplasia. N. Engl. J.Med. 354:557-66 (Pubitemid 43209103)
81. Barry MJ, Meleth S, Lee JY, et al. 2011. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms. JAMA 306:1344-51
82. Andriole GL, McCullum-Hill C, Sandhu GS, et al. 2013. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J. Urol. 189:486-92